According to our data, SGLT-2 inhibitors show the highest probability to be superior to GLP-1RA and DPP-4 inhibitors in terms of HHF and the composite renal outcome, while GLP1-RA are superior to DPP-4 inhibitors for both outcomes
The conflicting data regarding ulcerative colitis risk warrants caution for IBD patients until more data is available
You will be asked to undergo several tests, such as checking your vital signs, blood pressure, and blood count
Combining glutathione and semaglutide is an increasingly common question among patients exploring comprehensive metabolic wellness
A 72 settimane, alla dose massima commerciale equivalente di 17,2 mg al giorno corrispondente ai 36 mg della formulazione sperimentale usata in ATTAIN-1 il farmaco produce una perdita di peso media dell11,2% nei pazienti con obesit senza diabete (Wharton et al., 2025)